Gabapentin (Neurontin)
GABA analogue that does not bind GABA receptors but modulates calcium channels. Used for neuropathic pain, seizures, and anxiety. Not hepatically metabolized.
Projected serum levels — 300 mg, twice daily
Maintenance schedule: 300 mg twice daily (oral).
Modeled steady state after ~1 days: peak ≈ 109 mg, trough ≈ 24.0 mg body load. Population-based estimate over 15 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Anticonvulsant
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 6 h
- Common dose
- 300 mg
- Suggested maximum
- 3.6k mg/day
- Reference dose range
- 100–3.6k mg (single dose)
- Suggested cadence
- twice daily
- Validated against
- 300 mg oral — Cmax 2.7 mg/L at 3 h
Documented interactions
-
danger
7-Hydroxymitragynine (7-OH) + Gabapentin (Neurontin)
FDA black box warning equivalent: gabapentinoids combined with opioids dramatically increase risk of respiratory depression and death. 7-Hydroxymitragynine is a potent mu-opioid agonist — this…
-
danger
Codeine + Gabapentin (Neurontin)
Gabapentin + opioids significantly increases respiratory depression risk. FDA black box warning.
-
danger
Heroin / 6-MAM + Gabapentin (Neurontin)
Gabapentin + opioids causes severe respiratory depression. Heroin already carries extreme overdose risk.
-
danger
Hydrocodone + Gabapentin (Neurontin)
Gabapentin + opioids significantly increases respiratory depression risk.
-
danger
Morphine + Gabapentin (Neurontin)
Gabapentin + opioids significantly increases respiratory depression risk.
-
danger
Oxycodone + Gabapentin (Neurontin)
Gabapentin + opioids significantly increases respiratory depression risk. FDA black box warning.
Serum checks 12 modeled interaction pairings for gabapentin (neurontin) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial
Pivotal RCT of 229 patients found gabapentin (up to 3600 mg/day) significantly reduced postherpetic neuralgia pain by 33% compared to 8% for placebo, establishing its role in neuropathic pain.
-
A randomized, double-blind, placebo-controlled trial of gabapentin for the treatment of generalized anxiety disorder
RCT found gabapentin 600-3600 mg/day significantly reduced anxiety symptoms compared to placebo in patients with generalized anxiety disorder.
-
Pharmacological management of neuropathic pain: evidence-based recommendations
Systematic review and meta-analysis recommending gabapentin as a first-line treatment for neuropathic pain, with NNT of 6.3 for 50% pain relief.
3 published studies referenced in the app, each with a plain-language summary.